Stay updated on 89Zr-Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the 89Zr-Pembrolizumab in NSCLC Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov page revision label updates from **v3.5.2** to **v3.5.3**, indicating a site/version release with no change to the study’s informational content.SummaryDifference0.1%

- Check12 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check41 days agoChange DetectedAdded a new version label 'Revision: v3.5.0' and removed 'Revision: v3.4.3' from the site metadata.SummaryDifference0.1%

- Check48 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a minor site version update with no visible changes to core content or functionality.SummaryDifference0.1%

- Check76 days agoChange DetectedAdded Revision: v3.4.2 and removed the funding-lapse notice along with Revision: v3.4.1.SummaryDifference0.5%

- Check83 days agoChange DetectedAdded a site-wide government funding lapse notice indicating possible delays in updates and support availability. Updated the site revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to 89Zr-Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.